-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-516052-17-01
10
Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
-
2024-517030-17-00
4
Newly diagnosed or relapsing Giant-cell arteritis
-
2024-518146-25-00
5
patients with atrial fibrillation and preserved left ventricular eject
-
2024-518251-31-00
5
patients hospitalized for a septic shock with hypercontractlity
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
-
2025-524697-42-00
5
Pleural infections
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-511226-32-00
6
2025-05-07
pleurodesis surgery for cure of pneumothorax
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2024-519620-24-01
5
2026-06-01
ANCA-associated vasculitis
-
2025-522109-39-00
5
2026-05-22
Alcoholic hepatitis
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2023-508930-33-00
4
2026-01-30
Non-infectious active cryoglobulinemia vasculitis who are either refra
-
2024-511437-35-00
10
2026-01-05
Patients aged 18-65 years old with newly diagnosed previously untreate
-
2022-501557-36-00
4
2025-12-19
PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-512653-25-00
5
2025-06-26
IgA nephropathy
-
2024-519219-32-00
5
2025-06-23
Heart Failure With Reduced Ejection Fraction